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Abstract
Only few cell-based test methods are described by Organisation for Economic Co-operation and Development (OECD) 
test guidelines or other regulatory references (e.g., the European Pharmacopoeia). The majority of toxicity tests still 
falls into the category of non-guideline methods. Data from these tests may nevertheless be used to support regulatory 
decisions or to guide strategies to assess compounds (e.g., drugs, agrochemicals) during research and development if 
they fulfill basic requirements concerning their relevance, reproducibility and predictivity. Only a method description of 
sufficient clarity and detail allows interpretation and use of the data. To guide regulators faced with increasing amounts 
of data from non-guideline studies, the OECD formulated Guidance Document 211 (GD211) on method documentation 
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continuous malformation index. Any combination of these inde-
pendent elements results in a different overall test method.
2  Compliance issues with OECD Guidance  
Document 211 (GD211) 
The key literature on how to describe non-guideline methods is 
OECD Guidance Document 211 (GD211) (OECD, 2017). In line 
with reports by many others (Freedman et al., 2015; Vogt et al., 
2016; Hair et al., 2019), our own survey of the scientific literature 
has indicated that method descriptions still show an enormous het-
erogeneity in quality, detail and scope. Moreover, the clarity of the 
information, as well as the format that is used to provide the in-
formation, varies widely. This makes the extraction of necessary 
information as well as the use and interpretation of data produced 
using the method difficult. We further found that the items required 
to be addressed in GD211 are understood and interpreted in differ-
ent ways by the users, or sometimes not understood at all. 
Part of this might be attributable to the fact that GD211 looks at 
non-guideline methods from a regulatory perspective, i.e., it ex-
plicitly provides a format for reporting non-guideline methodolo-
gy so that it can be used by regulatory toxicologists for the safety 
assessment of chemicals. It asks for information that is of specific 
value for regulators (e.g., information on validation, predictivity, 
standardization, applicability domain, etc.), but does not provide 
detailed background information on why regulators need such in-
formation and what they use it for. Experience has shown that the 
target audience, which includes method developers in academia 
or fundamental research, is not necessarily familiar with the un-
derlying regulatory background.
Another reason for apparent non-compliance is that GD211 is a 
brief and highly condensed document. It often covers several distinct 
features of tests in a single question. Test developers may not consid-
er all the different aspects of such a complex question without more 
specific guidance, and thus some issues may be missed entirely.
From the information recipient’s point-of-view, non-compli-
cance is not the only problem. Also, finding and retrieving the in-
formation within a report prepared in a not fully-standardized for-
mat can be a difficult task. For instance, it may be a time-consum-
ing task to find out whether some information is absent or whether 
it is only placed or mentioned in another context than usual.
1  Main test elements 
Test, assay, test system, test method… All these terms are found 
in the literature and in discussions, but they need some definition 
to allow for specification of their background and requirements. 
“Test” is the shortest term and thus a good place to start: a toxico-
logical “test” is a procedure to determine, in a quantifiable manner 
(with respect to damage and dose/concentration), whether a sub-
stance may harm/incapacitate an organism, a cell, or an essential 
component thereof. The terms “assay” and “test method” are used 
interchangeably with “test”.
A test has various elements that are independent of one another to 
a large degree (Schmidt et al., 2017). The five main elements are: the 
test purpose (see Section 4), the test system, the exposure scheme, 
the endpoint, and the prediction model. Thus, the “test system” is 
one element of the “test method” and must not be confused with it. 
As this often causes confusion among non-specialists, it deserves 
some further explanation. The in vivo test method for acute toxicity 
assessment is a good example to explain the problem. The over-
all test method is defined by a test guideline, e.g., OECD TG 423 
(acute oral toxicity) (OECD, 2002). The test system is, e.g., mouse, 
fasted for > 3 h prior to dosing; the exposure scheme involves 
single dosing by gavage and continued observation for 14 days; 
the endpoint is the number/percentage of dead animals; and the 
prediction model converts the test data into toxicity classes defined 
by the United Nation’s Globally Harmonized System (GHS), e.g., 
category 2 (comprising compounds with an LD50 in the range of 
5-50 mg/kg bodyweight). Clearly, the mouse is the test system and 
not the test method. Each element of the test method may be mod-
ified independently, e.g., changing from oral to dermal exposure; 
using time to death as endpoint; employing a binary prediction 
model (toxic/non-toxic) and using rats instead of mice. Any such 
change results in a new, different test method that may no longer be 
in accordance with the guideline method. 
The same principles apply to cell-based assays, i.e., in vitro 
methods or new approach methods (NAM). For example, the test 
system may be neurons in 2D culture or neural organoids or liver 
cells; the exposure scheme may be 24 h exposure of cells cultured 
in standard medium plus test chemical or 72 h exposure in a spe-
cial medium, with or without re-addition of test chemical every 
24 h; the prediction model may be binary (toxic/non-toxic) or it 
may use a composite measure of several endpoints to define a 
for the purpose of safety assessment. As GD211 is targeted mainly at regulators, it leaves scientists less familiar with 
regulation uncertain as to what level of detail is required and how individual questions should be answered. Moreover, 
little attention was given to the description of the test system (i.e., cell culture) and the steps leading to it being established 
in the guidance. To address these issues, an annotated toxicity test method template (ToxTemp) was developed (i) to 
fulfill all requirements of GD211, (ii) to guide the user concerning the types of answers and detail of information required, 
(iii) to include acceptance criteria for test elements, and (iv) to define the cells sufficiently and transparently. The fully 
annotated ToxTemp is provided here, together with reference to a database containing exemplary descriptions of more 
than 20 cell-based tests.
Abbreviations 
AC, acceptance criteria; GD, guidance document; OECD, Organisation for Economic Co-operation and Development; SOP, standard operating procedure; TG, test guideline; 
ToxTemp, toxicological test methods template
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veloped for regulatory purposes. In this domain, the element “test 
purpose” plays a special role: Beyond the primary test purpose 
(e.g., determination of cytotoxicity), the results of a test may also 
be used for a secondary, regulatory purpose (regulation), and even 
a tertiary purpose (e.g., modelling a potential hazard in the popula-
tion). Consider, e.g., in vitro tests used to predict Globally Harmo-
nized System (GHS) classifications (e.g., moderate or strong skin 
sensitizer or eye irritant) (secondary purpose), which in turn are 
used to model the potential chemical hazard to which workers or 
the general population may be exposed (tertiary purpose). 
Test developers might not be familiar with the limitations and 
requirements demanded of their test when it is to be used for 
secondary (or tertiary) purposes, and this may in the end lead to 
misinterpretation of results obtained from a test method used for 
purposes that it was not originally designed for. The problem is 
further complicated by the fact that an apparently simple regula-
tory statement (e.g., “The substance is a skin sensitizer.”) in real-
ity represents the outcome of a highly complex decision system 
based on a regulatory framework that has evolved over several 
decades, with paradigms and implicit assumptions that are often 
not obvious to the outsider. 
To avoid such problems, communication between developers 
and regulatory recipients needs to be as transparent, comprehen-
sive and precise as possible. Description of a test method, espe-
cially of the test purpose, in a way that allows such communica-
tion is essential to achieve this.
5  Distinctions between a test method description  
and the overall testing process
Reproducible toxicological research necessitates the comprehen-
sive description of the testing process. Good information on this 
can be found in the series of guidance on Good Laboratory Prac-
tice (GLP) (e.g., OECD, 2005) or in the OECD Guidance Doc-
ument on Good In Vitro Methods Practice (GIVIMP) (OECD, 
2018). Several helpful tools are available, e.g., from the Science 
in Risk Assessment and Policy (SciRAP3) web resource, the 
DB-ALM methods summary (adapted from GD211), the EURL- 
ECVAM test submission template (used for structuring informa-
tion for test validation), or the ALTEX BenchMarks series (Kisitu 
et al., 2019; Krebs et al., 2018). 
Several earlier EU-funded projects devoted considerable re-
sources to harmonize test method descriptions (Kinsner-Ovaska-
inen et al., 2009; Rovida et al., 2014), and similar activities are 
taking place in the USA (Flood et al., 2017). The overall reporting 
of in vitro experiments (data and methods) has been addressed by 
an NC3Rs initiative (RIVER) (Prior et al., 2019), large stakehold-
er workshops organized by CAAT-Europe (Hartung et al., 2019), 
and on the regulatory level (OECD harmonized templates for da-
ta reporting (OHT); OHT 201- Intermediate effects4 is especially 
relevant).
3  Annotations and guiding questions for a test method  
template
The problems that test developers face when trying to comply 
with the questions raised in GD211 may best be illustrated us-
ing an analogy from an entirely different field. Let us assume 
that a police recruit is asked in a questionnaire to “indicate body 
measures”. Some would answer by giving only their height and 
weight. Others may include their shoe size and special measures 
for jackets and trousers. Few would give their head circumfer-
ence (required for the uniform hat) and/or their glove size. Possi-
bly even fewer would think to provide information on their sight, 
i.e., data essential for ordering sunglasses (e.g., whether they are 
myopic, distance between the eyes, etc.). 
In the course of the European research project EU-ToxRisk 
(Daneshian et al., 2016), compliance of project case study results 
with GD211 became an important issue. While trying to imple-
ment high-quality assay documentation within the project, we re-
alized that hardly any of the senior scientists and none of the ju-
nior faculty fully understood the requirements of GD211. 
How are situations as exemplified above (police recruit or 
EU-ToxRisk examples) best avoided? How can it be ensured that 
all required information (i) is reported, (ii) is presented in a struc-
tured way so that the recipients can verify its completeness, and 
(iii) can be found easily? Two major strategies towards this goal 
are (a) to sub-divide complex questions into sets of more simple 
questions, each dealing with a single, defined issue, and (b) to 
explain the questions by adding additional notes, comments and 
guiding questions. These measures help to structure the answer 
and ensure that all relevant aspects are considered. 
Such guidance is provided by the test method template (Tox-
Temp) shown in a compact version as Box 1 and provided as a 
printable version including additional notes and examples in the 
supplementary file1. Tab. 1 gives a synoptic overview of all items/
questions of GD211 and of the respective counterparts in the Tox-
Temp (see also the supplementary file1 for the detailed compar-
ison). Moreover, an online methods database, based on the Tox-
Temp, is under construction2. Using Tab. 1  should enable anyone 
accustomed to the structure of GD211 to retrieve all relevant test 
method information from the database.
4  Understanding the test purpose
Any test (toxicological or not) is developed to probe a test hypoth-
esis (e.g., whether a substance is toxic or not). The test design will 
always reflect that purpose and test parameters will ideally be op-
timized in order to achieve maximum certainty about whether the 
hypothesis should be accepted or rejected. 
It is a basic scientific principle that test results should – with-
in limits – only be used for the purpose they were designed for. 
This is not trivial for in vitro or new approach methods (NAM) de-
1 doi:10.14573/altex.1909271s
2 https://eu-toxrisk.douglasconnect.com/public/
3 http://scirap.org/Page/Index/aa44f63a-ce5d-4f26-bac3-346c27b34eb0/reporting-checklist
4 http://www.oecd.org/ehs/templates/harmonised-templates-intermediate-effects.htm 
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Box. 1: Documentation of a test method and its readiness status, guided by a test method questionnaire  
A print version of the complete test method questionnaire including notes and examples can be found in the supplementary file1.
1.  Overview
1.1 Descriptive full-text title
Provide a descriptive title using normal language without technical terms or acronyms.
1.2 Abstract
Please describe in no more than 200 words the following:
Which toxicological target (organ, tissue, physiological/biochemical function, etc.) is modelled? (8.1)
Which test system and readout(s) are used? (4.1; 5.2)
Which biological process(es) (e.g. neurite outgrowth, differentiation) and/or toxicological events (e.g. oxidative stress, cell death) are 
modelled/reflected by your test method? (8.1)
To which (human) adverse outcome(s) is your test method related or could be related? (8.1; 9.2; 9.3)
Which hazard(s) do(es) your test method (potentially) predict? (8.1; 8.6)
Does the test method capture an endpoint of current regulatory studies? (9.5)
If the method has undergone some form of validation/evaluation, give its status. (9.4)
2. General information
2.1 Name of test method
Provide the original/published name, as well as the potential tradename.
2.2 Version number and date of deposition 
Provide the original deposition date of first version and date of current version.
2.3 Summary of introduced changes in comparison to previous version(s)
This only applies to updated versions. If this is the original version, state “original version”. 
2.4 Assigned data base name
Normal text names often do not uniquely define the method. Therefore, each method should be assigned a clearly and uniquely defined 
data base name.
These are some example data base names generated in the EU-ToxRisk project: 
UKN1a_DART_NPC_Diff_6D_02
UKN1b_DART_NPC_Diff_4D_01
UKN2a_DART_NC_Migr_24h_04
The name is assembled (in more generic terms) from the following elements:
Axa_B_C_D_E
Axa: mandatory part of the identifier allowing unambiguous identification
A: Abbreviation/acronym of the partner depositing the assay
x: Consecutive number (referring to the partner’s assay number)
a: Sub-specifier (for variants, i.e. very similar assays but e.g. different readout or medium); not mandatory, but ‘Axa’ must be specific  
(i.e. clearly identifying) for each assay variant.
B: Indication of the main intended use (max. 5 letters), e.g. DART, Neuro, Liver, Lung, Renal, Redox, Stress...
C: Specifier of test system, e.g. cell type such as NPC (neural precursor cells), NC (neural crest), Hep (liver cells), REN (kidney cells),  
PUL (lung cells) (max. 4 letters)
D: Identification of test endpoint, e.g. Diff_6D = Differentiation for 6 days; exp_24 h = exposure for 24 hours; RNA_6h = transcriptome  
after 6 hours (use max. 15 signs altogether; if desired in 2-3 blocks), name (and acronym) of the project partner home organisation. 
E: version number.
2.5 Name and acronym of the test depositor
Include affiliation.
2.6 Name and email of contact person
Provide the details of the principal contact person. 
2.7 Name of further persons involved 
For example, the principal investigator (PI) of the lab, the person who conducted the experiments, etc.
2.8	Reference	to	additional	files	of	relevance
Supply number of supporting files.
Describe supporting files (e.g. metadata files, instrument settings, calculation template, raw data file, etc.).
3. Description of general features of the test system source
3.1 Supply of source cells 
Describe briefly whether the cells are from a commercial supplier, continuously generated by cell culture, or obtained by isolation from 
human/animal tissue (or other). 
Krebs et al.
ALTEX 36(4), 2019 686
3.2 Overview of cell source component(s)
Give a brief overview of your biological source system, i.e. the source or starting cells that you use. 
Which cell type(s) are used or obtained (e.g. monoculture/co-culture, differentiation state, 2D/3D, etc.)? 
If relevant, give human donor specifications (e.g. sex, age, pool of 10 donors, from healthy tissue, etc.).
3.3	Characterization	and	definition	of	source	cells
List quantitative and semi-quantitative features that define your cell source/starting cell population. For test methods that are based on 
differentiation, describe your initial cells, e.g. iPSC, proliferating SH-SY5Y; the differentiated cells are described in section 4.
Define cell identity, e.g. by STR signature (where available), karyotype information, sex (where available and relevant), ATCC number, 
passage number, source (supplier), sub-line (where relevant), source of primary material, purity of the cells, etc.
Describe defining biological features you have measured or that are FIRMLY established (use simple listing, limit to max. 0.5 pages), 
e.g. the cells express specific marker genes, have specific surface antigens, lack certain markers, have or lack a relevant metabolic or 
transporting capacity, have a doubling time of x hours, etc. 
Transgenic cell lines have particular requirements concerning the characterization of the genetic manipulation (type of transgene, type  
of vector, integration/deletion site(s), stability, etc.).
Organoids and microphysiological systems (MPS) may need some special/additional considerations as detailed in Pamies et al. (2018)  
and Marx et al. (2016), e.g. ratio of cell types used, percent of normal cells in tumor spheroids created from resected tissue; derivation 
of cells for re-aggregating brain cultures.
3.4 Acceptance criteria for source cell population
Describe the acceptance criteria (AC) for your initial cells (i.e. the quality criteria for your proliferating cell line, tissue for isolation, 
organism, etc.). Which specifications do you consider to describe the material, which quality control criteria have to be fulfilled (e.g. 
pathogen-free)? Which functional parameters (e.g. certain biological responses to reference substances) are important? 
For iPSC maintenance: How do you control pluripotency? How stable are your cells over several passages? Which passage(s) are 
valid?
For primary cells: Show stability and identity of supply; demonstrate stability of function (e.g. xenobiotic metabolism). 
Quantitative definitions for AC should be given based on this defining information. Exclusion criteria (features to be absent) are also 
important. 
As in 3.3., special/additional requirements apply to genetically-modified cells and microphysiological systems.
3.5 Variability and troubleshooting of source cells
Name known causes of variability of the initial cells/source cells.
Indicate critical consumables or batch effects (e.g. relevance of the plate format and supplier, batch effects of fetal calf serum (FCS) or 
serum replacement, critical additives like type of trypsin, apo-transferrin vs. holo-transferrin, etc.).
Indicate critical handling steps and influencing factors (e.g. special care needed in pipetting, steps that need to be performed quickly,  
cell density, washing procedures, etc.).
As in 3.3., special/additional requirements apply to genetically-modified cells and microphysiological systems, e.g. dependence on 
matrix chemistry and geometry, dependence on microfluidics system, consideration of surface cells vs core cells, etc.
Give recommendations to increase/ensure reproducibility and performance.
3.6	Differentiation	towards	the	final	test	system
Describe the principles of the selected differentiation protocol, including a scheme and graphical overview, indicating all phases, 
media, substrates, manipulation steps (medium change/re-plating, medium additives, etc.). Special/additional requirements apply to 
microphysiological systems and organoids: e.g. cell printing, self-aggregation/self-organisation process, interaction with the matrix, 
geometrical characterization (size/shape), etc.
3.7 Reference/link to maintenance culture protocol 
Provide the SOP of the general maintenance procedure as a database link. This should also include the following information:
How are the cells maintained outside the experiment (basic cell propagation)? 
How pure is the cell population (average, e.g. 95% of iPSC cells Oct4-positive)? 
What are the quality control measures and acceptance criteria for each cell batch?
Which number(s) passage(s) can be used in the test?
Is Good Cell Culture Practice (GCCP) and/or Good In Vitro Method Practice (GIVIMP) followed?
How long can same cell batches be used? 
How are frozen stocks and cell banks prepared? 
For primary cells: how are they obtained in general and what are they characterized for (and what are inclusion and exclusion criteria). 
4.	 Definition	of	the	test	system	as	used	in	the	method
4.1 Principles of the culture protocol
Describe the test system as it is used in the test. 
If the generation of the test system involves differentiation steps or complex technical manipulation (e.g. formation of microtissues),  
this is described in 3.6.
Give details on the general features/principles of the culture protocol (collagen embedding, 3D structuring, addition of mitotic inhibitors, 
addition of particular hormones/growth factors, etc.) of the cells that are used for the test. 
What is the percentage of contaminating cells; in co-cultures what is the percentage of each subpopulation? 
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Are there subpopulations that are generally more sensitive to cytotoxicity than others, and could this influence viability measures?  
Is it known whether specific chemicals/chemical classes show differential cytotoxicity for the cell sub-populations used?
4.2 Acceptance criteria for assessing the test system at its start
What are the endpoint(s) that you use to control that your culture(s) is/are as expected at the start of toxicity testing (e.g. gene 
expression, staining, morphology, responses to reference chemicals, etc.)? 
Describe the acceptance criteria for your test system, i.e. the quality criteria for your cells/tissues/organoids: Which endpoints do  
you consider to describe the cells or other source material, which parameters are important? 
Describe the (analytical) methods that you use to evaluate your culture (PCR, ATP measurement) and to measure the acceptance  
criteria (AC). 
Which values (e.g. degree of differentiation or cell density) need to be reached/should not be reached?
Historical controls: How does your test system perform with regard to the acceptance criteria, e.g. when differentiation is  
performed 10 times, what is the average and variation of the values for the acceptance criteria parameters)? Indicate actions if  
the AC are not met. 
Examples: cell are > 90% viable, or > 98% of cells express marker x (e.g. AP-2), or > 80% of the cells attach, etc.
4.3 Acceptance criteria for the test system at the end of compound exposure
Describe the acceptance criteria for your test system, i.e. the quality criteria for your cells/tissues/organoids: Which endpoints do you 
consider to describe the cells or other source material, which parameters are important? 
Which values (e.g. degree of differentiation or cell density) need to be reached/should not be reached?
Historical controls: How does your test system perform with regard to the acceptance criteria, e.g. when differentiation is performed  
10 times, what is the average and variation of the values for the acceptance criteria parameters)? Indicate actions if the AC are  
not met. 
Examples: Usual neurite length is 50 ±15 µm; experiments with average neurite length below 25 µm in the negative controls (NC) are 
discarded. Usual nestin induction is 200 ±40 fold, experiments with inductions below 80-fold for NC are discarded. 
4.4 Variability of the test system and troubleshooting
Give known causes of variability for final test system state.
Indicate critical consumables or batch effects (e.g. plate format and supplier, batch effects of FCS or serum replacement, additives).
Indicate critical handling steps, and/or influencing factors identified (e.g. special care needed in pipetting, steps that need to be 
performed quickly, cell density).
Indicate positive and negative controls and their expected values, and accepted deviation within and between the test repeats.
Give recommendations to increase/ensure reproducibility and performance.
4.5 Metabolic capacity of the test system
What is known about endogenous metabolic capacity (CYP system (phase I); relevant conjugation reactions (phase II))?
What is known about other pathways relevant to xenobiotic metabolism?
What specific information is there on transporter activity?
4.6 Omics characterization of the test system
Are there transcriptomics data or other omics data available that describe the test system (characterization of cells without compounds)? 
Briefly list and describe such data.
Indicate the type of data available (e.g. RNASeq or proteomics data). 
Refer to data file, data base or publication. 
4.7	Features	of	the	test	system	that	reflect	the	in vivo tissue
Give information on where the test system differs from the mimicked human tissue and which gaps of analogy need to be considered.
4.8 Commercial and intellectual property rights aspects of cells
Are there elements of the test system that are protected by patents or any other means?
4.9 Reference/link to the culture protocol
Fill only if section 3 has not been answered. 
Provide the SOP for the general maintenance procedure as a database link. This should also include the following information:
How are the cells maintained outside the experiment (basic cell propagation)? 
How pure is the cell population (average, e.g. 95% of iPSC cells Oct4-positive)? 
What are the quality control measures and acceptance criteria for each cell batch?
Which number(s) passage(s) can be used in the test?
Is Good Cell Culture Practice (GCCP) and/or Good In Vitro Method Practice (GIVIMP) followed?
How long can same cell batches be used? 
How are freezing stocks and cell banks prepared? 
For primary cells: How are they obtained in general and what are they characterized for (and what are inclusion and exclusion criteria).
5. Test method exposure scheme and endpoints
5.1 Exposure scheme for toxicity testing
Provide an exposure scheme (graphically, show timelines, addition of medium supplements and compounds, sampling, etc.), within  
the context of the overall cell culture scheme (e.g. freshly re-plated cells or confluent cells at start, certain coatings, etc.). 
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Include medium changes, cell re-plating, whether compounds are re-added in cases of medium change, critical medium supplements, 
etc.
5.2 Endpoint(s) of the test method
Define the specific endpoint(s) of the test system that you use for toxicity testing (e.g. cytotoxicity, cell migration, etc.).
Indicate whether cytotoxicity is the primary endpoint.
What are secondary/further endpoints?
Also describe here potential reference/normalization endpoints (e.g. cytotoxicity, protein content, housekeeping gene expression) that 
are used for normalization of the primary endpoint. 
5.3 Overview of analytical method(s) to assess test endpoint(s)
Define and describe the principle(s) of the analytical methods used. Provide here a general overview of the method’s key steps (e.g. 
cells are fixed or not, homogenized sample or not, etc.), sufficient for reviewers/regulators to understand what was done, but not in all 
detail for direct repetition.
If you have two or more endpoints (e.g. viability and neurite outgrowth), do you measure both in the same well, under same conditions 
in parallel, or independently of each other?
For imaging endpoints: Explain in general how quantification algorithm or how semi-quantitative estimates are obtained and how many 
cells are imaged (roughly). 
5.4 Technical details (of e.g. endpoint measurements)
Provide information on machine settings, analytical standards, data processing and normalization procedures. 
For imaging endpoints: provide detailed algorithm.
This information should also be covered in an SOP, preferably in DB-ALM format (see link in 6.6). 
5.5	Endpoint-specific	controls/mechanistic	control	compounds	(MCC)
MCC are chemicals/manipulations that show biologically plausible changes of the endpoint. List such controls (up to 10), indicate why 
you consider them as MCC, and describe expected data on such controls. Highlight the compounds to be used for testing day-to-day 
test performance, i.e. for setting acceptance criteria (AC).
If available, indicate MCC that each increase or decrease the activity of the relevant pathway. Do pathway inhibitions or activations 
correlate with the test method response?
5.6 Positive controls
What chemicals/manipulations are used as positive controls? Describe the expected data on such controls (signal and its uncertainty)?
How good are in vivo reference data on the positive controls? Are in vivo relevant threshold concentrations known?
5.7	Negative	and	unspecific	controls
What chemicals/manipulations are used as negative controls? Describe the expected data on such controls (signal and its uncertainty)? 
(Such data define the background noise of the test method)
What is the rationale for the concentration setting of negative controls?
Do you use unspecific controls? If yes, indicate the compounds and the respective rationale for their use and the concentration 
selection.
5.8 Features relevant for cytotoxicity testing
Does the test system have a particular apoptosis sensitivity or resistance?
Is cytotoxicity hard to capture for minor cellular subpopulations?
In multicellular systems, which cell population is the most sensitive? Are specific markers known for each cell population? 
Are there issues with distinguishing slowed proliferation from cell death? 
For repeated/prolonged dosing: Is early death and compensatory growth considered?
For very short-term endpoints (e.g. electrophysiology measured 30 min after toxicant exposure): Is a delayed measure of cytotoxicity 
provided?
5.9 Acceptance criteria for the test method
Which rule do you apply to test whether a test run is within the normal performance frame?
How do you document this decision?
Indicate actions if the AC are not met.
5.10 Throughput estimate
Indicate “real data points per month” (not per week/per quarter, etc.): count three working weeks per month. Each concentration is a 
data point. Necessary controls that are required for calibration and for acceptability criteria are NOT counted as data points. All technical 
replicates of one condition are counted as one single data point (see notes for explanation)
Indicate possibility/extent of repeated measures (over time) from same dish.
Explain your estimate.
6. Handling details of the test method
6.1 Preparation/addition of test compounds
Give an overview of the range of volumes, particular lab ware/instruments for dispensing, temperature/lighting considerations, particular 
media/buffers for dilution, decision rules for the solvent, tests of solubility as stocks and in culture medium, etc. 
How are compound stocks prepared (fold concentration, verification, storage, etc.)?
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How are dilutions prepared? What solvent is used? Is filtering used to obtain sterility?
How does the final addition to the test system take place?
Give details of addition of test compounds to test systems (e.g. in which compartment of compartmentalized cultures, in which volume, 
before after or during medium change, etc.).
6.2 Day-to-day documentation of test execution
How are day-to-day procedures documented (type of ‘lab book’ organisation, templates)?
Define lab-specific procedures used for each practical experiment on how to calculate test compound concentrations (and to document 
this).
How are plate maps defined and reported?
Detailed information should also be covered in an SOP, preferably in DB-ALM format (see link in 6.6). 
6.3 Practical phase of test compound exposure
How is the time plan of pipetting established, followed, and documented?
How is adherence to plate maps during pipetting documented?
What are the routine procedures to document intermediate steps with potential errors, mistakes and uncertainties?
How are errors documented (e.g. pipetting twice in one well)? 
How are the plate wells used sequentially – following which pattern?
Detailed information should also be included in an SOP, preferably in DB-ALM format (see link in 6.6). 
6.4 Concentration settings
How is the concentration range of test compounds defined (e.g. only single concentrations, always 1:10 serial dilutions or variable 
dilution factors, ten different concentrations, etc.)? Is there a rule for defining starting dilutions?
For functional endpoints that may not provide full concentration-response, how is the test concentration defined? E.g. EC10 of viability 
data are usually tested for gene expression endpoints.
Detailed information should also be included in an SOP, preferably in DB-ALM format (see link in 6.6). 
6.5 Uncertainties and troubleshooting
What types of compounds are problematic, e.g. interference with analytical endpoint, low solubility, precipitation of medium components, 
etc.?
What experimental variables are hard to control (e.g. because they are fluorescent)?
What are critical handling steps during the execution of the assay?
Robustness issues, e.g. known variations of test performance due to operator training, season, use of certain consumable or unknown 
causes, etc.
Describe known pitfalls (or potential operator mistakes).
6.6 Detailed protocol (SOP)
Ideally the SOP follows the DB-ALM or a comparable format:
https://ecvam-dbalm.jrc.ec.europa.eu/home/contribute
Refer to additional file(s) (containing information covered in sections 3 and 4), containing all details and explanations. 
Has the SOP been deposited in an accessible data base? 
Has the SOP been reviewed externally and if yes, how?
6.7 Special instrumentation
Does the method require specialized instrumentation that is not found in standard laboratories? 
Is there a need for custom-made instrumentation or material? 
Is there a need for equipment that is not commercially available (anymore)?
6.8 Possible variations
Describe possible variations, modifications and extensions of the test method:
a) other endpoints, 
b) other analytical methods for same endpoint, 
c) other exposure schemes (e.g. repeated exposure, prolonged exposure, etc.),
d) experimental variations (e.g. use of a specific medium, presence of an inhibitor or substrate that affects test outcome, etc.)
6.9 Cross-reference to related test methods
Indicate the names (and database names) of related tests and give a short description (including a brief comment on differences to the 
present method). 
If the test method has been used for high throughput transcriptomics or deep sequencing as alternative endpoint, this should be 
indicated.
7. Data management
7.1 Raw data format
What is the data format? 
Raw data: give general explanation. Upload an exemplary file of raw data (e.g. Excel file as exported out of plate reader).  
Provide an example of processed data at a level suitable for general display and comparison of conditions and across experiments and 
methods. 
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If the file format is not proprietary or binary, include a template. This will help other users to provide their data in a similar way to the 
general data infrastructure. 
Example as used in EU-ToxRisk: Excel sheet with columns specifying line number, assay name, date of experiment, identifier for 
reference to partner lab book, compound, concentration (in: -log[M]), line number of corresponding control, number of replicates, 
endpoints, data of endpoint(s), etc.
7.2 Outliers
How are outliers defined and handled?
How are they documented?
Provide the general frequency of outliers.
7.3 Raw data processing to summary data
How are raw data processed to obtain summary data (e.g. EC50, BMC15, ratios, PoD, etc.) in your lab?
Describe all processing steps from background correction (e.g. measurement of medium control) to normalization steps (e.g. if you 
relate treated samples to untreated controls).
7.4	Curve	fitting
How are data normally handled to obtain the overall test result (e.g. concentration response fitting using model X, determination of EC50  
by method Y, use of EC50 as final data)?
How do you model your concentration response curve (e.g. LL.4 parameter fit) and which software do you use (e.g. GraphPad Prism,  
R, etc.)?
Do you usually calculate an uncertainty measure of your summary data (e.g. a 95% confidence interval for the BMC or a BMCL), and 
with which software?
Can you give uncertainty for non-cytotoxicity or no-effect? 
How do you handle non-monotonic curve shapes or other curve features that are hard to describe with the usual mathematical fit 
model?
7.5 Internal data storage
How and how long are raw and other related data stored? 
What backup procedures are used (how frequently)? 
How are data versions identified?
7.6 Metadata
How are metadata documented and stored (lab book, Excel files, left in machine, etc.)? 
How are they linked to raw data?
What metadata are stored/should be stored?
7.7	Metadata	file	format
Give example of the metadata file (if available). 
If metadata or data format (see 7.1) are pre-defined in the project, state here “as pre-defined in project xxx” (e.g. EU-ToxRisk). 
8. Prediction model and toxicological application
8.1	Scientific	principle,	test	purpose	and	relevance
What is the scientific rationale to link test method data to a relevant in vivo adverse outcome?
Which toxicological target (organ, tissue, physiological/biochemical function, etc.) is modelled?
Which biological process(es) (e.g. neurite outgrowth, differentiation) are modelled/reflected by your test method? 
Which toxicological events (e.g. oxidative stress, cell death) are modelled/reflected by your test method? 
To which (human) adverse outcome(s) is your test method related?
Which hazard(s) do(es) your test method (potentially) predict?
8.2 Prediction model
Provide the statistics of your benchmark response (threshold and variance):
(i) For dichotomized data, provide your prediction model. When do you consider the result as toxic or not toxic? 
(ii) For pseudo-dichotomized outcomes (two classes with borderline class in between): define borderline range.
(iii) For multi-class or continuous outcomes: provide definitions and rationale.
What is the rationale for your threshold? This can be on a mathematical (e.g. 3-fold standard deviation) or a biological basis (e.g. below  
80% viability).
Is there a toxicological rationale for the threshold settings and definitions of your prediction model?
What are the limitations of your prediction model?
What is a ‘hit’ if the test is used in screening mode (= hit definition, if different from above)?
8.3 Prediction model setup
How was the prediction model set up (using which test set of chemicals to train the model; using probing with what kind of classifiers/
statistical approaches)?
Has the prediction model been tested (what was the test set of chemicals)? List chemicals or give n, if n > 50.
Is the process documented (publication)?
Does the prediction model (PM) apply to changes to both sides of controls (up/down)? If the PM is one-sided (e.g. toxicants leading 
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to a decrease vs. control), how are data in the opposite direction handled and interpreted? If the PM is two-sided, do different rules, 
characteristics and interpretations apply to the two sides (e.g. is a decrease in viability or an increase in viability both interpreted as an 
effect/toxicity; are thresholds and performance characteristics to both sides the same?).
8.4 Test performance 
Indicate here basic performance parameters or, if possible, preliminary estimates (label as such): Baseline variation (noise) within 
assays AND between assays. 
What is the signal/noise ratio (signal = standard positive control)? 
Is the z-factor determined?
Give the specificity of the test method. How is it determined?
Give the sensitivity of the test method. How is it determined?
Give measures of the uncertainty of your test method. How are they determined?
What is the detection limit (required change of endpoint to become measurable)?
If available, give limit of detection (LOD) and limit of quantification (LOQ). 
What are inter-operator variations?
Are there data of ‘historical controls’ over a longer time period? 
8.5 In vitro – in vivo extrapolation (IVIVE)
Describe parameters important for the determination of free compound concentrations in the medium.
Indicate the lipid and protein content of the medium and the cells. 
Indicate the volume of the cells.
Indicate volume (medium volume) and surface area of culture dish.
Is there information/literature on IVIVE strategies/data in the test?
Has the test been used earlier for IVIVE?
Are there special considerations that are relevant for IVIVE (e.g. potential for compound accumulation due to frequent medium changes 
and compound re-addition, glycoprotein (MDR1) expression, capacity for xenobiotic metabolism of test system)?
8.6 Applicability of test method
Which compounds is the test likely to pick up correctly, where is it likely to fail? 
How does the test method react to mixtures and UVCBs?
Are there areas (according to industry sector, compound chemistry, physical-chemical properties) that need to be excluded from testing, 
or that are particularly suitable?
Which compound class cannot be detected (e.g. neurotransmitters for which the receptors are not expressed, endocrine disruptors in 
absence of respective pathway)?
Are any compounds known to interfere with the test system (e.g. fluorescent or colored chemicals)?
8.7 Incorporation in test battery
Does the test fit into a test battery? If yes, into which test battery and are there any restrictions?
Indicate potential strengths and weaknesses of the system in a test battery (e.g. method is a good confirmation assay, good for creating 
alerts, mechanistic follow-up, screening, etc.). 
Compare performance to similar tests. 
Which gaps in a known or potential battery does the test method fill?
Should the test preferentially be used in the first tier or later tiers, are complementary assays required or is it a stand-alone method?
9. Publication/validation status
9.1 Availability of key publications
Refer to published literature on the test AND indicate in detail deviations from published descriptions (e.g. plastic plate supplier, cell 
number, endpoint measurement, timing, etc.).
Provide the most relevant publications that describe/give a comprehensive overview of (a) your test system and/or (b) your test method. 
Describe what aspects are covered therein.
Give a prioritized (according to importance) list of further publications on the test method or its application.
Give short comments on which type(s) of information can be obtained from these publications (e.g. contains test chemical lists, contains 
more positive/negative controls, contains validation against other tests, contains incorporation in test battery, demonstrates use by  
other lab, etc.).
9.2  (Potential) linkage to AOPs
Indicate whether the test method has been or could be linked to an AOP (or several AOPs) and in which form (e.g. test of KE activation). 
Can the test method cover an AOP MIE/KE?
Reference relevant AOP and if in AOP-wiki, refer to status.
9.3 Steps towards mechanistic validation
Indicate/summarize information on mechanistic validation, e.g. by omics approaches or by use of endpoint specific controls (MCC;  
section 5.5).
Has it been explored in how far the system reflects human biology, signaling, tissue organization relevant to the form of toxicity to be 
assessed (e.g. nigrostriatal neurons should contain dopamine, liver tests relevant to cholestasis may need to contain bile canalicular 
structures, etc.)?
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6  Why data are meaningless without a test method  
description
There is an intricate relationship between a test method and the 
data it generates. It is evidently clear that a test method itself has 
no value in toxicology if it does not generate data. The reverse 
condition is often overlooked: Is there any value in data if the test 
method is not sufficiently documented or disclosed? This ques-
tion is not easily answered. One reason for this is that “naked 
data”, i.e., data without reference to a test method, do not exist 
for in vivo tests. Most data inherently contain some information 
on test conditions. For instance, if one talks about data on the 
LD50 (lethal dose, 50%) test for oral toxicity in rat (example data: 
4.5 ±1 mg/kg bodyweight), then the data contain information on 
The many types of essential information can be grouped as be-
longing to four partially overlapping packages: (i) the overall test 
method description, (ii) the technical test procedure (as outlined 
in a standard operating procedure (SOP) involving, e.g., defined 
labware, consumables and pipetting steps), (iii) the characteriza-
tion of test and reference materials/chemicals, and (iv) all issues 
relating to data processing and archiving. In a wider sense, an ad-
ditional package (v) addresses the test purpose, the test limitations 
(i.e., information on its applicability) and the criteria to be used 
for interpreting test results. Here, the focus is on the overall test 
method description (packages i + v). Notably, this description also 
involves some information from the other packages (ii-iv) – not in 
full detail but as far as required to provide an overall understand-
ing of the test method.
Are there interventions (knock-out, knockdown, chemical inhibitors, specific pathway triggering) that support the use of the test for 
certain toxicological questions and that corroborate expectations to the test system?
Is there a form of mechanistic validation? 
Do toxicant-altered genes (or other biomarkers) correspond to changes in mimicked human tissue (after poisoning or in relevant 
pathologies)?
9.4 Pre-validation or validation
Indicate/summarize activities for test qualification, pre-validation or validation.
Indicate e.g. ring trials, full (pre-)validations. 
Give an overview of compounds or libraries that have been tested.
9.5 Linkage to (e.g. OECD) guidelines/regulatory use
Indicate whether the test method is linked to an OECD Test Guideline (how, and which) or other regulatory guidance (e.g. EMA).
10. Test method transferability
10.1 Operator training
What experience is required? 
How are new operators trained in your laboratory? 
How much training/experience is required for smooth assay performance?
10.2 Transfer
Has the test system been transferred to other labs? 
Has the test method been used by various operators (over a long time period)? 
Has the test method been transferred to other labs?
Is there data on inter-laboratory variability?
What are procedures and how was the performance (experience) of the transfer?
11.	Safety,	ethics	and	specific	requirements
11.1	 Specific	hazards;	issues	of	waste	disposal
Are there special legal requirements for running the test in your lab; are there special hazards associated with the test that may affect 
operators, bystanders, others (e.g. through waste).
11.2 Safety data sheet (SDS)
Are the SDSs for all hazardous reagents used in the test method available?
Are the SDSs for all hazardous test compounds stored?
Describe where and how the SDSs are stored internally. How is safe handling ensured?
Is the exposure scenario for the hazardous reagents used in the test method available?
11.3	 Specific	facilities/licenses	
Are special permits (e.g. genetic work, stem cells, radioactivity, etc.) required?
Are special facilities required? 
Is special ethical approval necessary (indicate approval document).
11.4 Commercial aspects/intellectual property of material/procedures
List elements of the test method (e.g. consumables, chemicals, analytical methods, equipment) that are protected by patents or any 
other means. Indicate the type of protection and where the element (or license for it) may be obtained.
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(GCCP) are considered and adhered to (Coecke et al., 2005). Yet, 
many problems have been described in this regard. For instance, 
many cells have been misidentified or cross-contaminated with 
other cells (Drexler et al., 2003; Gignac et al., 1993; Horbach and 
Halffman, 2017; Masters, 2002; Nardone, 2007, 2008; Stacey, 
2000; Stacey et al., 1992), or microbiologically contaminated 
(e.g., with mycoplasms). Even two batches of cells from a single 
source can differ significantly (Ben-David et al., 2018; Frattini et 
al., 2015; Kleensang et al., 2016; Liu et al., 2019). Even more im-
portantly, this form of identification only applies to cell cultures 
that are based on well-defined cell lines. Even in apparently sim-
ple cases (e.g., using the HepG2 cell line or primary rodent he-
patocytes or neuronal cells), cultures of the same cells have dif-
ferent properties depending on their culture medium, cell density, 
cell-matrix, etc. (Brigelius-Flohe et al., 1995; Latta et al., 2000; 
Leist et al., 1999; Ramaiahgari et al., 2014; Delp et al., 2019; 
Falsig et al., 2006; Gantner et al., 1996; Gerhardt et al., 2001; 
Zimmer et al., 2012).
2. Determination of the cells’ genotype. Sometimes, genotyping, 
e.g., by short tandem repeat (STR) profiling, by extensive single 
nucleotide polymorphism (SNP) profiling or by array compar-
ative genome hybridization (aCGH) (Zhang et al., 2017; Mat-
suda, 2017; Cao et al., 2015) is used for defining a test system. 
However, the genotype gives no information on the differentia-
tion state or the epigenetic state. This problem is also not circum-
vented by complete genome sequencing (Gutbier et al., 2018).
3. Reference to the original source. For primary cells, this has in 
the past been considered as sufficiently defining (e.g., for he-
patocytes, neurons, broncho-alveolar cells or blood cell popula-
tions) (Kruglikov et al., 1976; Schildknecht et al., 2011, 2013; 
Gerhardt et al., 2001). However, it is now ackowldeged that this 
approach does not account for the large variability in cell pu-
rity, viability, activation/inflammatory state, de-differentiation, 
history within the organism (e.g., drug treatment), etc. Even 
the culture setup can make a dramatic difference. This is ex-
emplified by broncho-alveolar cells grown submerged in me-
dium (standard type of culture) or at the air-liquid interphase, 
which promotes baso-lateral polarization. Even more variation 
is introduced if one considers that the cells may be confluent 
(with tight junctions) or non-confluent, at an early or late pas-
sage number, etc.
4. Reference to a differentiation protocol. Many modern test sys-
tems are derived from stem cells that have been differentiated. If 
they are obtained from commercial sources, the protocol used to 
generate the cells is mostly confidential, and variability between 
lots is unknown. Even if all protocol details are known, the is-
sue still remains that one given cell (with a defined genome) can 
give rise to dozens of differentiated progeny cell types and that 
those may have multiple health and proliferation states (Stiegler 
et al., 2011; Zimmer et al., 2011). The differentiation protocol is 
not sufficiently defining for the final population.
Is it at all possible to unambiguously define a cell culture? At the 
present state of the art, this may indeed not be possible (Gutbier 
et al., 2018; Liu et al., 2019) unless the use of the culture is spec-
ified. With a specific use scenario in mind (use of the cells in a 
the test system (rat) and the exposure scheme (oral dosing, tim-
ing). Also, information on the endpoint and a normalization of the 
dose to a test unit can be easily derived from the data. In the above 
example, this would be death (as endpoint) and dose per body 
weight unit (as data normalization procedure). Without such in-
herent test method information, a data point (e.g., 5 mg or 117 g) 
would be meaningless. 
The situation is even more extreme for cell-based tests or new 
approach methods (NAM) in general. Data may be something like 
“10%”. Depending on the test, this may refer to a 10% reduction in 
viability (i.e., hardly any effect), 10% remaining viability (a dras-
tic effect), a 10% increase in neurite growth (a moderate effect of 
unclear relevance) or 10% remaining level of acetylcholine activ-
ity (extreme adversity). Even if this was specified, it would not be 
possible to interpret the data, as they may have been obtained after 
exposure for 5 min to 10 nM compound or after exposure for one 
year to 1 mM compound. This example, trivial as it may appear, 
is intended to explain an important point: Data have no meaning 
if the respective test method with all its elements is not disclosed 
fully and transparently (Leist and Hengstler, 2018). 
Large studies (mainly focusing on animal experimentation) have 
reported that test method descriptions are often poor (Freedman et 
al., 2015; Hair et al., 2019; Vogt et al., 2016; Ingre-Khans et al., 
2019). This lack of test method transparency may contribute sig-
nificantly to reproducibility issues often reported for biomedical re-
search (Ioannidis, 2012; Begley and Ellis, 2012; Prinz et al., 2011; 
Hartung et al., 2019). In the toxicological context, data obtained 
using test method descriptions that are not sufficiently clear cannot 
be considered “valid”, i.e., “suitable for a regulatory context or in 
a context where major scientific or commercial decisions depend 
on the data interpretation” (Hartung and Leist, 2008; Leist et al., 
2014). Given the experience that many essential details on meth-
ods are often not disclosed in scientific publications, it is of prime 
importance to define meticulously what is required of a method de-
scription and also to provide guidance on structuring this informa-
tion (OECD, 2018; Leist et al., 2010, 2012; Hartung et al., 2019).
7  How to define a cell
The test system of many in vitro test methods is a cell culture (in 
two- or three-dimensional format). Therefore, the definition of the 
cells is an important element of a test method description. This is 
also clearly stated in GD211. However, the problem of defining 
a cell appears to have been underestimated – especially with re-
spect to many modern, highly dynamic and complex cell cultures 
(Pamies et al., 2017, 2018; Balmer et al., 2012; Bal-Price et al., 
2015). To appreciate the problem, it is helpful to initially look at 
some attempts to define a cell and to examine the problems asso-
ciated with them:
1. Quoting the catalogue number or another apparent cell identi-
fier. Often the ATCC (American Type Culture Collection) num-
ber, the colleague who provided the cells, or the tissue from 
which the (primary) cells were obtained is given. This may work 
to some extent if all principles of Good Cell Culture Practice 
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Tab. 1: Synopsis of information found in OECD GD211 and the extensive test method description questionnaire (ToxTemp) 
compiled here 
The left column lists all chapters/items of GD211 (original numbering) (OECD, 2017), while the right column indicates where the corresponding 
information can be found in ToxTemp. Also, GD211 sometimes lists several important issues without assignment to sub-items (see, e.g., item 
3 “Data interpretation and prediction model” of GD211). Such compilations of several aspects are often covered by several distinct chapters of 
ToxTemp. Two examples for the diverging levels of detail are highlighted in blue: (i) chapter 2.3 of GD211 addresses the test system (cells). This 
information is covered in 15 sub-chapters of ToxTemp; (ii) in chapter 2.6 of GD211, there are several sub-items (bullets) that are highly divers. 
These are therefore covered in ToxTemp in very different chapters. A more detailed comparison is found in Tab. S21.
GD211 chapter and chapter name Information to be found in chapter(s)  
  of ToxTemp
1
2.
2.1
2.2
2.3
2.4
2.5
2.6
2.7
2.8
2.9
3.
3.1
3.2
3.3
3.4
4.
4.1
4.2 
4.3
4.4
5.
5.1
6.
7.
General information
1.1 Assay Name (title) / 1.2 Summary / 1.3 Date of MD / 1.4 MD author(s) and 
contact details / 1.5 Date of MD update(s) and contacts / 1.6 Developer(s) 
laboratory and contact details / 1.7 Date of assay development and/or 
publication / 1.8 Reference(s) to scientific papers / 1.9 Information about 
the assay in relation to proprietary elements / 1.10 Information about the 
throughput / 1.11 Status of method development and uses / 1.12 Abbreviations 
and Definitions
Test	method	definition
Purpose of the test method
Scientific principle of the method
Tissue, cells or extracts utilised in the assay and the species source
Metabolic competence of the test system
Description of the experimental system exposure regime
Response and response measurement
• Response here makes reference to any biological effect, process or activity 
  that can be measured 
 
 
• Specify precisely and describe the response and its measurement 
 
• Specify the precise response or activity investigated as applicable e.g. “IC50”
• And how it is calculated
Quality / Acceptance criteria
Known technical limitations and strengths
Other related assays that characterise the same event as in 2.1
Data interpretation and prediction model
Assay response(s) captured in the prediction model
Data analysis
Explicit prediction model
Software name and version for algorithm/prediction model generation
Test method performance
Robustness of the method
Reference chemicals/chemical libraries, rationale for their selection and other 
available information
Performance measures/predictive capacity
Scope and limitations of the assay
Potential regulatory applications
Context of use
Bibliography
Supporting information
1.1; 1.2; 2.2; 2.3; 2.5; 2.6; 2.7; 4.8; 5.10; 8.1; 
9.1; 9.4; 9.5; 10.2; 11.4
4.7; 8.1; 8.7; 9.2; 9.3
4.7; 5.5; 8.1; 9.2; 9.3
3.1 - 3.7; 4.2 - 4.8
4.5
5.1; 5.6; 5.7; 5.10; 6.4; 6.7; 8.6; 11.3 
1.2; 5.2; 5.3; 7.3; 7.4; 8.1; 9.3
5.2 Endpoint(s) of the test method
1.2 Abstract
8.1 Scientific principle, test purpose and  
      relevance
9.3 Steps towards mechanistic validation
5.2 Endpoint(s) of the test method
5.3 Overview on analytical method(s) to  
      assess test  endpoint(s)
7.3 Raw data processing to summary data
7.4 Curve fitting
3.2; 3.4; 4.2; 4.3; 5.4; 5.5; 5.6; 5.7; 6.7; 7.1; 
7.5; 8.4; 9.5 
5.8; 8.6; 8.7
6.9
8.2; 8.3; 9.2; 9.3
5.2; 8.2
7.3; 7.4; 8.4
8.2
7.4
8.4; 10.2
5.5; 5.6; 5.7; 8.3; 8.6 
7.4; 8.3; 9.4
8.2; 8.6; 8.7
8.1
8.2; 8.4; 8.6; 8.7
9.1
2.8
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8  Acceptance criteria (AC)
The ToxTemp places a strong emphasis on acceptance criteria, 
not only for the overall test method but also for the test system 
at different stages. Going one step further, the questions address 
specification of the test system at the start and at the end of test-
ing. This is necessary in many cases when the cell culture changes 
significantly during the test (chemical exposure phase). Examples 
for this are the use of differentiating stem cells (shift of subpop-
ulations) or of primary cells (shift of composition, differentiation 
state, viability, activation state and other features). 
The definition and application of acceptance criteria (AC) en-
sures that the specifications of test method elements are within a 
given test method), a fit-for-purpose definition is feasible and re-
alistic (Lorge et al., 2016).
The ToxTemp includes two sections that help to better define 
cells. First, a cell culture is not seen as one static and given system. 
Therefore, it contains a whole suite of questions, notes and guiding 
questions that address different stages of the cells and are designed 
to define the entire process leading from a maintenance culture (or 
an original tissue) to the final test system (Fig. 1). Second, the defi-
nition of acceptance criteria (AC) for the test system is explained 
and requested. This ensures that the state of the cell culture can be 
defined in a pre-determined range that is fit-for-purpose concern-
ing the use of the test system within the given test method (Blaau-
boer et al., 2012; Hansson et al., 2000; Hirt et al., 2000). 
Fig. 1: Documentation of cell culture stages relevant for their use in an in vitro test method 
The ToxTemp presented here assesses test system features and the respecitive acceptance criteria (AC) at different stages. In chapter 
3, the original source of cells and their characteristics (green cells) as well as their differentiation/maturation (yellow cells) are covered. 
Chapter 4 focuses on the test system stages at the beginning of the test, i.e., at the start of chemical exposure, and at the final stage 
(end of test; red cells). Four examples of cellular test systems and their stages during test preparation and testing are given. In addition, 
exemplary processes (e.g., proliferation) that can change a test system, which should therefore be documented and taken into account for 
a comprehensive test method documentation, are indicated.  
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readiness is defined more broadly, allowing for different readiness 
stages, depending on the purpose/application of the test method 
(e.g., screening versus regulatory use) (Bal-Price et al., 2018; Frit-
sche et al., 2017). Within such a framework, different elements 
of a test method may be evaluated separately, e.g., in a modular 
validation process (Hartung et al., 2004), or according to spec-
ified readiness criteria and scoring lists (Bal-Price et al., 2018). 
The ToxTemp gives guidance on how to provide such detailed 
information.
10  Conclusions
Interactions with many researchers from academia and industry 
have shown that the most common roadblock to practical imple-
mentation of GD211 is a lack of understanding of the require-
ments, and that additional notes and guiding questions are nec-
essary to overcome this. Moreover, it was recognized that a com-
prehensive test method description needs more focus on practical 
aspects of the testing process (such as details on data handling or 
of the test system) and on the documentation of method limita-
tions and troubleshooting. We found that the project partners of 
the EU-ToxRisk project were all able, compliant and motivated to 
deliver comprehensive method descriptions when guided by the 
ToxTemp. This shows that there is a positive attitude and a good 
motivation amongst test developers to describe their assay. A tool/
template such as the one presented here is likely to act as support 
and catalyst towards a culture of fully transparent and complete 
test method descriptions.
In conclusion, the ToxTemp presented here will make it easier 
for the many test developers not deeply familiar with regulatory 
environments to describe their assays in sufficient detail. It will al-
so allow to better understand and compare different testing meth-
ods (e.g., for the same endpoint). If the ToxTemp were broadly 
implemented, it would not only give guidance to test developers 
but could change the overall culture of method documentation. 
Scientists fostered in an environment that values sound descrip-
tions of methods and data will not only become better (more re-
liable) researchers but will also be better trained for entering re-
sponsible positions in industry and regulatory agencies.
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